Efficacy and safety of PCSK-9 inhibitors in patients with acute coronary syndrome: a systematic review and network meta-analysis
Abstract Background Acute coronary syndrome (ACS) remains a leading cause of global cardiovascular morbidity and mortality, with elevated low-density lipoprotein cholesterol (LDL-C) being a key modifiable risk factor. Despite statin therapy, many patients fail to achieve optimal LDL-C targets, highl...
Saved in:
| Main Authors: | Guoying Kao, Chuan Chen, Ying Zhang, Yi Xu, Gang Xu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | BMC Cardiovascular Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12872-025-05070-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis
by: Yuhua Jiang, et al.
Published: (2025-02-01) -
Application of a PCSK9 inhibitor in the treatment of lipid disorders – a comprehensive literature
by: Piotr Rzyczniok, et al.
Published: (2025-05-01) -
Lower body mass index is associated with the achievement of target LDL in patients using PCSK9 inhibitors in Taiwan
by: Kuan-Chieh Tu, et al.
Published: (2025-03-01) -
PCSK9 inhibitors reduces arterial stiffness in patients with acute coronary syndrome
by: Wang Liang, et al.
Published: (2025-01-01) -
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to tackle central nervous system diseases: role as a promising approach
by: Xiaoxiao Zheng, et al.
Published: (2025-07-01)